Effect of Samarium on the Relief of Pain Due to Vertebral Metastases
|ClinicalTrials.gov Identifier: NCT00374751|
Recruitment Status : Completed
First Posted : September 11, 2006
Last Update Posted : April 29, 2015
Cancer cells may spread from the primary site to the vertebrae resulting in their deformity. The standard treatment for this case is removal of the cancer deposits in the vertebra and filling the induced cavity with a cement like substance.
We are studying the effects (good or bad) of adding samarium (a radioactive substance) to the cement that is injected into the induced cavity.
|Condition or disease||Intervention/treatment||Phase|
|Cancer Metastasis Pain||Drug: Samarium (153SM)||Phase 1 Phase 2|
- Patients with bone metastases will be identified and discussed in the weekly joint Neuroscience meeting held in Radiation Oncology Department.
- If the patient is eligible to this study, the protocol will be offered to him/her. If the patient accepts; informed consent will be obtained.
- The case will be scheduled jointly by Neurosurgeon and Radiation Oncologist.
- Radiation physicist orders the radioactive samarium.
During the procedure:
- Neurosurgical procedure ( kyphoplasty/vertebroplasty) is performed as standard using . mild general sedation and local anesthesia.
- Once a cavity is identified in fluoroscopy, the trocar is secured. The volume and pressure of the kyphoplasty balloon are recorded.
- According to standard practice; only the radiation team (Radiation oncologist, Physicist) is handling the radioactive material. All work is done under sterile conditions.
- Two mCi. of Samarium is prepared after serial dilution steps under radiation precautions in the department of radiation oncology and material is transferred to OR.
- 0.5ml of "Head Cement" is administered first to act as a seal.
- The Samarium is then introduced into the vertebral cavity using a 2-way valve by the Radiation Oncologist. Total of 0.5ml (Samarium+0.2ml radio opaque material)
- The "Foot cement" (0.5 ml) is then introduced via the same 2-way valve into the vertebral cavity by the neurosurgeon to flush any remains of radioactivity in the system.
- The two way valve is then removed and the rest of kyphoplasty/vertebroplasty is ensued as per their ordinary protocol.
- Final volume of cement injected is recorded.
- After securing the wound, all devices, syringes, gloves and basins used for handling the radioactive substance are collected in a "red bag" and stored by radiation safety officer in the hot lab. till full radioactive decay.
- The room is scanned after patient's discharge, any spillage should be reported to radiation safety officer and normal procedures for environmental protection are ensued.
- Normal neurosurgical recovery room protocol is employed. No radiation precautions needed.
- Patient can be discharged home. No delays because of radiation precautions
- Once patient is cleared, a nuclear imaging scan is obtained with Gamma camera. The ratio of uptake in the vertebra to background is calculated. Moreover, Full body scan is obtained to identify other areas of uptake if any.
- A second nuclear imaging scan is done on the 4th day of the procedure (Two half Lives) to document significant decay and calculate dose.
- MRI/CT scan of the area treated should be done in 4 weeks to assess outcome.
- Clinical follow up is obtained at 2, 4 weeks and in 3 months. Careful pain score assessment is included in each time (Use Study Flow Sheet)
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||29 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I/II Study of the Use of Vertebral Intracavitary Cement and Samarium (VICS) for Painful Vertebral Metastases|
|Study Start Date :||May 2006|
|Primary Completion Date :||January 2014|
Drug: Samarium (153SM)
- To determine the effect of intravertebral injection of Samarium on the relief of pain [ Time Frame: 6 months ]
- To evaluate the effect of this procedure on the size of the vertebral metastatic deposits [ Time Frame: 6 months ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00374751
|United States, New York|
|New York Methodist Hospital|
|Brooklyn, New York, United States, 11215|
|Principal Investigator:||Hani Ashamalla, MD, FCCP||New York Methodist Hospital|